Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Aardvark’s lead candidate ARD-101 is being investigated in a Phase III study for hyperphagia in Prader-Willi syndrome.

Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...

If you continue to have this issue please contact [email protected]. Adults receiving tirzepatide in the SURPASS trials had significant decreases in urine albumin-to-creatinine ratio.

US-based MicroAire Surgical Instruments has acquired NEOSYAD, a developer of technology for adipose tissue engineering. France-based NEOSYAD recently gained CE marking under the European Union’s ...

South Korea-based developer of RNAi therapeutics developer OliX Pharmaceuticals has announced a global licensing agreement with Eli Lilly.

Discover how small biotechs are innovating in the weight loss therapy market with new treatments targeting unique mechanisms ...

The biotech believes that azelaprag can amplify the weight loss achieved with tirzepatide and other obesity drugs, and also improve the body composition of treated patients by preserving muscle ...

What will it take for a clinical-stage biotech to break into the cardio space? One CEO thinks he has the answer.

At least nine patients using the glucagon-like peptide 1 (GLP-1) receptor agonists semaglutide and tirzepatide developed ophthalmic complications, of whom seven had nonarteritic anterior ischemic ...

US pharma major Eli Lilly today announced its financial results for the fourth quarter of 2024 and detailed 2025 financial ...